Add to ORKGOBJECTIVE: The objective of this EBM review is to determine whether or not Apixaban is effective for the prevention of stroke in patients with non-valvular atrial fibrillation. STUDY DESIGN: Review of three English language primary studies published all published in 2011. DATA SOUCRES: Three double-blind randomized control trials found using the Cochrane Database and PubMed. OUTCOME(S) MEASURED: Outcomes measured were occurrence of stroke (TIA or CVA), systemic embolism, major bleeding or clinically relevant non-major bleeding, and incidence of death. RESULTS: Apixaban 2.5mg and 5mg were both superior to Warfarin in the prevention of stroke or systolic embolism and also decreased the rate of intracranial hemorrhage or other clinically relev...
Atrial fibrillation (AF) is associated with increased risk of stroke that can be attenuated with vit...
Background: Apixaban is superior to aspirin for the prevention of stroke in patients with atrial fib...
Background: In the ARISTOTLE trial, the rate of stroke or systemic embolism was reduced by apixaban ...
This drug information question and answer sheet discusses the use of apixaban (Eliquis) for the prim...
Background and purpose: The use of oral anticoagulant therapy for stroke prevention in atrial fibril...
BACKGROUND The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillati...
Background: The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillat...
Item does not contain fulltextBACKGROUND: Vitamin K antagonists are highly effective in preventing s...
In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARIS...
BackgroundVitamin K antagonists are highly effective in preventing stroke in patients with atrial fi...
Item does not contain fulltextBACKGROUND: In the ARISTOTLE trial, the rate of stroke or systemic emb...
Contains fulltext : 88254.pdf (publisher's version ) (Closed access)Atrial fibrill...
BACKGROUND: We studied (1) the rates of stroke or systemic embolism and bleeding in patients with at...
Background: Various treatment strategies to treat AF and reduce its complications have been develope...
Atrial fibrillation (AF) is associated with increased risk of stroke that can be attenuated with vit...
Atrial fibrillation (AF) is associated with increased risk of stroke that can be attenuated with vit...
Background: Apixaban is superior to aspirin for the prevention of stroke in patients with atrial fib...
Background: In the ARISTOTLE trial, the rate of stroke or systemic embolism was reduced by apixaban ...
This drug information question and answer sheet discusses the use of apixaban (Eliquis) for the prim...
Background and purpose: The use of oral anticoagulant therapy for stroke prevention in atrial fibril...
BACKGROUND The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillati...
Background: The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillat...
Item does not contain fulltextBACKGROUND: Vitamin K antagonists are highly effective in preventing s...
In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARIS...
BackgroundVitamin K antagonists are highly effective in preventing stroke in patients with atrial fi...
Item does not contain fulltextBACKGROUND: In the ARISTOTLE trial, the rate of stroke or systemic emb...
Contains fulltext : 88254.pdf (publisher's version ) (Closed access)Atrial fibrill...
BACKGROUND: We studied (1) the rates of stroke or systemic embolism and bleeding in patients with at...
Background: Various treatment strategies to treat AF and reduce its complications have been develope...
Atrial fibrillation (AF) is associated with increased risk of stroke that can be attenuated with vit...
Atrial fibrillation (AF) is associated with increased risk of stroke that can be attenuated with vit...
Background: Apixaban is superior to aspirin for the prevention of stroke in patients with atrial fib...
Background: In the ARISTOTLE trial, the rate of stroke or systemic embolism was reduced by apixaban ...